no more next years

Butch Garrity
Butch Garrity Member Posts: 1
edited March 2014 in Prostate Cancer #1
Thanks for all your posts....I was not diagnosed until my cancer hit stage 4. I had asked my doctor at 48 for a psa screening but he told me not to bother, he said come back in 2 years when you are 50. At 48 and a half when to the hospital with excrutiating back pain and they found a tumor breaking off pieces of my spine from prostrate cancer. I spent last year healing, and getting back into a routine, taking the kids to Hawaii this year. The specialist said I should have 6-8 years left, a year and a half ago. I hope that I can provide the best example for my kids, have gotten closer to more putting trips, adventures, hikes, or love off until next best to you all my prayers and thoughts are with you.


  • billydeetwo
    billydeetwo Member Posts: 2
    Keep it going Butch
    You have the right attitude. It is done, live with it, but enjoy it to the fullest for all the time you have. I have been fighting this bone cancer for almost 5 years, now undergoing Chemo, but am convinced that I am going to live to do all the things still on my Bucket List...and I haven't even finished making out that list.

    You have your priorities straight, and could do a lot of good to the people on this Board who do not have your strength of character.

    Keep smiling, and we will keep praying for you.

  • Member Posts: 49
    Keep on going Butch.
    I will pray for you Butch.
    It's all in his hands.
    God bless you.
  • shipjim
    shipjim Member Posts: 137 Member
    No more years
    Keep after it, there are new things all the time. Find a second or third opinion but don't quit. Read the posts by NODAWGS and his long fight. Keep us all up to date on what your doing. jj
  • Member Posts: 49
    Great news. I will post the article.
    Scientists kill cancer cells with "trojan horse"

    By Michael Perry Michael Perry – Mon Jun 29, 5:57 am ET

    SYDNEY (Reuters) – Australian scientists have developed a "trojan horse" therapy to combat cancer, using a bacterially-derived nano cell to penetrate and disarm the cancer cell before a second nano cell kills it with chemotherapy drugs.

    The "trojan horse" therapy has the potential to directly target cancer cells with chemotherapy, rather than the current treatment that sees chemotherapy drugs injected into a cancer patient and attacking both cancer and healthy cells.

    Sydney scientists Dr Jennifer MacDiarmid and Dr Himanshu Brahmbhatt, who formed EnGenelC Pty Ltd in 2001, said they had achieved 100 percent survival in mice with human cancer cells by using the "trojan horse" therapy in the past two years.

    The scientists plan to start human clinical trials in the coming months. Human trials of the cell delivery system will start next week at the Peter MacCullum Cancer Center at the Royal Melbourne Hospital and The Austin at the University of Melbourne.

    The therapy, published in the latest Nature Biotechnology journal, sees mini-cells called EDVs (EnGenelC Delivery Vehicle) attach and enter the cancer cell.

    The first wave of mini-cells release ribonucleic acid molecules, called siRNA, which switch off the production of proteins that make the cancer cell resistant to chemotherapy.

    A second wave of EDV cells is then accepted by the cancer cell and releases chemotherapy drugs, killing the cancer cell.

    "The beauty is that our EDVs operate like 'Trojan Horses' They arrive at the gates of the affected cells and are always allowed in," said MacDiarmid.

    "We are playing the rogue cells at their own game. They switch-on the gene to produce the protein to resist drugs, and we are switching-off the gene which, in turn, enables the drugs to enter."


    RNA interference, or RNAi, is designed to silence genes responsible for producing disease-causing proteins and is one of the hottest areas of biotechnology research. RNA was the basis of the 2006 Nobel Prize in medicine.

    Dozens of biotechnology companies are looking for ways to manipulate RNA to block genes that produce disease-causing proteins involved in cancer, blindness or AIDS.

    Brahmbhatt said that after treatment with conventional drug therapy, a large number of cancer cells die but a small percentage of the cells can produce proteins that make cancer cells resistant to chemotherapeutic drugs.

    "Consequently, follow-up drug treatments can fail. The tumors thus become untreatable and continue to flourish, ultimately killing the patient," said Brahmbhatt.

    "We want to be part of moving toward a time when cancers can be managed as a chronic disease rather than being regarded as a death sentence," he said.

    The Nature report said the mini-cells were "well tolerated with no adverse side effects or deaths in any of the actively treated animals, despite repeated dosing."

    "Significantly, our methodology does not damage the normal cells and is applicable to a wide spectrum of solid cancer types," said MacDiarmid.

    "The hope is that the benign nature of this EDV technology should enable cancer sufferers to get on with their lives and operate normally using out-patient therapy."

    (Editing by Alex Richardson)